PTGS2 and prostate carcinoma: Androgen-sensitive human prostate carcinoma cells (CWR22Rv1) were implanted in athymic nude mice, which were then treated with GTPs (0.1% dissolved in drinking water) and celecoxib (5 mg/kg), a COX-2 inhibitor, alone and in combination.